Screener
aTyr Pharma ATYR Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by aTyr Pharma in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: aTyr Pharma’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001339970-26-000053
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Purchases of property and equipment | (211) | (9) |
| Purchases of available-for-sale investment securities | (13,846) | (41,260) |
| Maturities of available-for-sale investment securities | 40,873 | 40,150 |
| Net cash provided by (used in) investing activities | 26,816 | (1,119) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock through option exercises | — | 19 |
| Proceeds from issuance of common stock through employee stock purchase plan | 16 | 79 |
| Proceeds from issuance of common stock from at-the-market offerings, net of offering costs | — | 36,691 |
Item 1. Financial Statements
FAQ
- What is aTyr Pharma's investing cash flow?
- aTyr Pharma (ATYR) reported investing cash flow of $15.32M in Q2 2026.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about aTyr Pharma's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude